Migraine patients with 6 or more headache days per month should be offered preventive therapy. Patients with 3-4 attacks who experience significant functional disability should also be offered preventive therapy.

Studies have shown that migraine preventive therapy is severely underutilized. Is this because of the current options and their shortcomings?

Here are some areas of current research per the National Headache Foundation:

Calcitonin Gene Related Peptide (CGRP): monoclonal antibodies targeting the receptor cell out the CGRP itself and small molecules targeting the receptor
Combination Drugs or New Delivery Systems: Dextromethorphan/quinidine
New Neurostimulators: Vagus nerve, Sphenopalatine ganglion, Supraorbital, Temporo-auricular, Occipital, and Transcutaneous magnetic (TMS)

The Manhattan Center for Headache and Neurology is dedicated to keeping up to date with the newest levels of treatments for our patients. Come, and be a part of our patient population and experience the commitment we have with our patients.